Voyager Therapeutics Inc (NASDAQ: VYGR) has experienced a rise in its stock price by 0.96 compared to its previous closing price of 3.13. However, the company has seen a gain of 5.69% in its stock price over the last five trading days. globenewswire.com reported 2025-03-31 that – Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study – – Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 – – Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data – LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease (AD).
Is It Worth Investing in Voyager Therapeutics Inc (NASDAQ: VYGR) Right Now?
Additionally, the 36-month beta value for VYGR is 0.96. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VYGR is 44.89M and currently, short sellers hold a 6.54% ratio of that float. The average trading volume of VYGR on April 18, 2025 was 372.26K shares.
VYGR’s Market Performance
VYGR stock saw a decrease of 5.69% in the past week, with a monthly decline of -22.74% and a quarterly a decrease of -37.55%. The volatility ratio for the week is 5.88%, and the volatility levels for the last 30 days are 7.51% for Voyager Therapeutics Inc (VYGR). The simple moving average for the past 20 days is -5.35% for VYGR’s stock, with a -46.94% simple moving average for the past 200 days.
Analysts’ Opinion of VYGR
Citigroup, on the other hand, stated in their research note that they expect to see VYGR reach a price target of $12. The rating they have provided for VYGR stocks is “Buy” according to the report published on December 02nd, 2024.
Wedbush gave a rating of “Outperform” to VYGR, setting the target price at $11 in the report published on November 29th of the previous year.
VYGR Trading at -18.64% from the 50-Day Moving Average
After a stumble in the market that brought VYGR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.91% of loss for the given period.
Volatility was left at 7.51%, however, over the last 30 days, the volatility rate increased by 5.88%, as shares sank -18.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.17% lower at present.
During the last 5 trading sessions, VYGR rose by +5.69%, which changed the moving average for the period of 200-days by -59.80% in comparison to the 20-day moving average, which settled at $3.34. In addition, Voyager Therapeutics Inc saw -44.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYGR starting from Ferguson Toby, who sale 10,086 shares at the price of $3.43 back on Apr 02 ’25. After this action, Ferguson Toby now owns 157,914 shares of Voyager Therapeutics Inc, valued at $34,595 using the latest closing price.
Sandrock Alfred, the President and CEO of Voyager Therapeutics Inc, sale 10,885 shares at $3.43 during a trade that took place back on Apr 02 ’25, which means that Sandrock Alfred is holding 430,931 shares at $37,336 based on the most recent closing price.
Stock Fundamentals for VYGR
Current profitability levels for the company are sitting at:
- -1.04 for the present operating margin
- 0.55 for the gross margin
The net margin for Voyager Therapeutics Inc stands at -0.81. The total capital return value is set at -0.24. Equity return is now at value -24.25, with -17.47 for asset returns.
Based on Voyager Therapeutics Inc (VYGR), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35.
Currently, EBITDA for the company is -83.29 million with net debt to EBITDA at 0.35. When we switch over and look at the enterprise to sales, we see a ratio of 1.84. The receivables turnover for the company is 17.81for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.56.
Conclusion
In conclusion, Voyager Therapeutics Inc (VYGR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
